ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients

Overview of attention for article published in Frontiers in Genetics, September 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,259 followers.

ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative ... https://t.co/1w5tpW1PSS

13 Dec 2021

Reply Repost Favourite

New article: ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients https://t.co/DkqrjfgLvk #lungcancer #oncology https://t.co/n9Y4sXuHoJ

24 Sep 2021

Reply Repost Favourite

New Research: ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients: Atezolizumab, an immune checkpoint inhibitor, has been approved for use in clinical practice… https://t.c

07 Sep 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.